Growth hormone (GH) stimulates somatic growth and regulates metabolism. Growth hormone–releasing hormone (GHRH) is the major stimulator and somatostatin is the major inhibitor of the synthesis and release of GH. GH controls synthesis of insulin-like growth factor 1 (IGF-1, also called somatomedin-C), which largely controls growth. Although IGF-1 is produced by many tissues locally, the liver is the major source of circulating IGF-1. The metabolic effects of GH are biphasic. GH initially exerts insulin-like effects, increasing glucose uptake in muscle and fat, stimulating amino acid uptake and protein synthesis in liver and muscle, and inhibiting lipolysis in adipose tissue. Several hours later, more profound anti–insulin-like metabolic effects occur. They include inhibition of glucose uptake and use, causing blood glucose and lipolysis to increase, which increases plasma free fatty acids.
GH-secreting tumors are largely sporadic, but genetic abnormalities in the X chromosome (X-linked acrogigantism), overexpression of the pituitary tumor transforming gene (PTTG), and mutations in the aryl hydrocarbon receptor–interacting protein (AIP) have been discovered. Many GH–secreting adenomas contain a mutant form of the Gs protein, which is a stimulatory regulator of adenylate cyclase. Cells with the mutant form of Gs protein secrete GH even in the absence of growth hormone–releasing hormone (GHRH). A few cases of ectopic GHRH-producing tumors, especially of the pancreas and lung, also have been described.
Symptoms and Signs of Gigantism and Acromegaly
This rare condition occurs if GH hypersecretion begins in childhood, before closure of the epiphyses. Skeletal growth velocity and ultimate stature are increased, but little bony deformity occurs. However, soft-tissue swelling occurs, and the peripheral nerves are enlarged. Delayed puberty Delayed Puberty Delayed puberty is absence of sexual maturation at the expected time. Diagnosis is by measurement of gonadal hormones (testosterone and estradiol), luteinizing hormone, and follicle-stimulating... read more or hypogonadotropic hypogonadism is also frequently present, resulting in a eunuchoid habitus (ie, a body build that is tall and slender with long extremities).
In acromegaly, GH hypersecretion usually starts between the 20s and 40s. When GH hypersecretion begins after epiphyseal closure, the earliest clinical manifestations are coarsening of the facial features and soft-tissue swelling of the hands and feet. Appearance changes, and larger rings, gloves, and shoes are needed. Photographs of the patient are important in delineating the course of the disease.
In adults with acromegaly, coarse body hair increases, and the skin thickens and frequently darkens. The size and function of sebaceous and sweat glands increase, such that patients frequently complain of excessive perspiration and offensive body odor. Overgrowth of the mandible leads to protrusion of the jaw (prognathism) and malocclusion of teeth. Cartilaginous proliferation of the larynx leads to a deep, husky voice. The tongue is frequently enlarged and furrowed. In long-standing acromegaly, costal cartilage growth leads to a barrel chest. Articular cartilaginous proliferation occurs early in response to GH excess, with the articular cartilage possibly undergoing necrosis and erosion. Joint symptoms are common, and crippling degenerative arthritis may occur.
Peripheral neuropathies occur commonly because of compression of nerves by adjacent fibrous tissue and endoneural fibrous proliferation. Headaches are common because of the pituitary tumor. Bitemporal hemianopia may develop if suprasellar extension compresses the optic chiasm. The heart, liver, kidneys, spleen, thyroid gland, parathyroid glands, colon, and pancreas are larger than normal; thyroid enlargement may be generalized or multinodular. Cardiac disease (eg, coronary artery disease Overview of Coronary Artery Disease Coronary artery disease (CAD) involves impairment of blood flow through the coronary arteries, most commonly by atheromas. Clinical presentations include silent ischemia, angina pectoris, acute... read more , cardiomegaly, valvular insufficiencies, sometimes cardiomyopathy Overview of Cardiomyopathies A cardiomyopathy is a primary disorder of the heart muscle. It is distinct from structural cardiac disorders such as coronary artery disease, valvular disorders, and congenital heart disorders... read more ) occurs in perhaps one third of patients, with a doubling in the risk of death due to cardiac disease. Hypertension Hypertension Hypertension is sustained elevation of resting systolic blood pressure (≥ 130 mm Hg), diastolic blood pressure (≥ 80 mm Hg), or both. Hypertension with no known cause (primary; formerly, essential... read more occurs in up to one third of patients. Snoring is a common symptom, and obstructive sleep apnea Obstructive Sleep Apnea Obstructive sleep apnea (OSA) consists of episodes of partial or complete closure of the upper airway that occur during sleep and lead to breathing cessation (defined as a period of apnea or... read more occurs in 40 to 50% of patients. Colonic polyps are increased as a result of GH excess. The risk of cancer, particularly of the gastrointestinal tract, increases 2-fold to 3-fold. GH increases tubular reabsorption of phosphate and leads to mild hyperphosphatemia. Impaired glucose tolerance occurs in nearly half the patients with acromegaly and in gigantism, but clinically significant diabetes mellitus Diabetes Mellitus (DM) Diabetes mellitus is impaired insulin secretion and variable degrees of peripheral insulin resistance leading to hyperglycemia. Early symptoms are related to hyperglycemia and include polydipsia... read more occurs in only about 10% of patients.
Galactorrhea Galactorrhea Galactorrhea is lactation in any men or in women who are not breastfeeding. It is generally due to a prolactin-secreting pituitary adenoma. Diagnosis is by measurement of prolactin levels and... read more occurs in some women with acromegaly, usually in association with hyperprolactinemia Etiology . However, galactorrhea may occur with GH excess alone, because GH itself stimulates lactation. Decreased gonadotropin secretion often occurs with GH-secreting tumors. About one third of men with acromegaly develop erectile dysfunction, and nearly all women develop menstrual irregularities or amenorrhea.
Diagnosis of Gigantism and Acromegaly
CT or MRI
Insulin-like growth factor 1 (IGF-1) levels
Usually growth hormone levels
Diagnosis can be made from the characteristic clinical findings. MRI of the sella is the imaging test of choice for diagnosis of pituitary adenoma. CT, MRI, or skull x-rays disclose cortical thickening, enlargement of the frontal sinuses, and enlargement and erosion of the sella turcica. X-rays of the hands show tufting of the terminal phalanges and soft-tissue thickening.
Serum IGF-1 should be measured in patients with suspected acromegaly; IGF-1 levels are typically substantially elevated (3-fold to 10-fold), and because IGF-1 levels do not fluctuate like GH levels do, they are the simplest way to assess GH hypersecretion. IGF-1 levels also can be used to monitor response to therapy.
Plasma GH levels are typically elevated. Blood should be taken before the patient eats breakfast (basal state); in normal people, basal GH levels are low or undetectable. Transient elevations of GH are normal, due to the pulsatile secretion of GH, and must be distinguished from pathologic hypersecretion. The degree of GH suppression after a glucose load remains the standard and thus should be measured in patients with elevated plasma GH; however, the results are assay-dependent, and the cutoff for normal suppression is controversial. Secretion in normal people is suppressed to < 1 ng/mL ([< 1 mcg/L] a cutoff of < 0.4 ng/mL [< 0.4 mcg/L] is often used) within 120 minutes of oral administration of 75 g of glucose. Most patients with acromegaly have substantially higher values. In some cases, basal plasma GH levels are also used in monitoring response to therapy.
CT or MRI of the sella should be done to look for a tumor. If a tumor is not visible, excessive secretion of pituitary GH may be due to a non-central nervous system tumor producing excessive amounts of ectopic GHRH. Demonstration of elevated levels of plasma GHRH can confirm the diagnosis. Lungs and pancreas may be first evaluated in searching for the sites of ectopic production.
Screening for complications, including diabetes Diabetes Mellitus (DM) Diabetes mellitus is impaired insulin secretion and variable degrees of peripheral insulin resistance leading to hyperglycemia. Early symptoms are related to hyperglycemia and include polydipsia... read more , heart disease, and gastrointestinal cancer, should be done at the time of diagnosis. Fasting plasma glucose levels, glycosylated Hb (HbA1C), or an oral glucose tolerance test can be done to test for diabetes. Electrocardiography and, preferably, echocardiography are done to detect heart disease. Colonoscopy is done to detect colon cancer. Follow-up screening depends on the results of the initial testing and the patient's response to treatment.
Treatment of Gigantism and Acromegaly
Surgery or radiation therapy
Sometimes pharmacologic suppression of GH secretion or activity
Selective removal of the pituitary tumor with surgery is considered first-line therapy for most patients. Patients with comorbidities that prevent safe surgical resection and those with unresectable tumors may be treated with primary medical therapy. Rates of remission after surgical resection are dependent on the size and degree of invasion of the pituitary adenoma and the experience of the neurosurgeon.
Surgical removal of the tumor is likely to have been curative if GH levels measured after a glucose load and IGF-1 levels reach normal values. If one or both values are abnormal, further therapy is usually needed. If GH excess is poorly controlled, hypertension, heart failure, and an increased mortality occur. Predictors of mortality in acromegaly include hypertension, age, use of radiation, and hypopituitarism, especially adrenocorticotropic hormone deficiency. Reduction of IGF-I and GH levels to the normal range seems to reduce mortality rates to normal.
In general, drug therapy is indicated if surgery is contraindicated, if surgery or radiation therapy has not been curative, or if radiation therapy is being given time to work. Drugs available for the treatment of acromegaly include those that target tumor secretion of GH and one that blocks GH at the level of the GH receptor.
Somatostatin receptor ligands are a mainstay of therapy because they decrease GH secretion from the pituitary tumor mediated through interactions predominately with the somatostatin subtype receptor-2 (SSTR-2). Drugs in this class include octreotide and lanreotide, which have high affinity for the SSTR-2 and come in short-acting (octreotide) and long-acting (octreotide LAR and lanreotide) preparations. Pasireotide, a somatostatin receptor ligand with affinity for SSTR-1, 2, 3, and 5, is also available in short- and long-acting preparations. All somatostatin receptor ligands may also cause tumor shrinkage.
Octreotide is started with a 20-mg intramuscular injection delivered monthly and titrated to an effective dose after the third injection. Effective doses range from 10 to 40 mg monthly. Lanreotide is given in doses of 60 to 120 mg monthly, with the possibility of extended dosing (120 mg every 6 to 8 weeks) in patients with well-controlled disease Pasireotide is generally considered if octreotide or lanreotide is unsuccessful in returning IGF-I levels to normal. Octreotide is also available in an oral preparation given twice daily.
Cabergoline, a dopamine agonist, has been used alone or in combination with a somatostatin receptor ligand and works by suppressing GH secretion at the pituitary. Cabergoline is typically used in mild disease and has the advantage of being an oral drug.
Pegvisomant, the GH receptor antagonist, is given as a daily subcutaneous injection and decreases IGF-I levels and symptoms but does not decrease GH levels or act on the pituitary tumor. Pegvisomant is given with a loading dose 40 mg subcutaneously under physician supervision followed by a maintenance dose of 10 mg subcutaneously once a day and titrated by 5-mg increments every 4 to 6 weeks, depending on IGF-I levels.
Radiation therapy may be used at any step of treatment but is typically used as primary therapy only when surgery is not available. Timing of radiation in the treatment of patients with acromegaly varies among institutions. Stereotactic radiation, delivering about 5000 cGy to the pituitary, is used, but GH levels may not fall to normal for several years. Treatment with accelerated protons (heavy particle radiation) permits delivery of larger doses of radiation (equivalent to 10,000 cGy) to the pituitary; such therapy poses higher risk of cranial nerve and hypothalamic damage and is available only in a few centers.
Hypopituitarism Generalized Hypopituitarism Generalized hypopituitarism refers to endocrine deficiency syndromes due to partial or complete loss of anterior lobe pituitary function. Various clinical features occur depending on the specific... read more commonly develops several years after irradiation. Because radiation damage is cumulative, proton beam therapy should not be used after conventional gamma-irradiation. A combined approach with both surgery and radiation therapy is indicated for patients with progressive extrasellar involvement by a pituitary tumor and for patients in whom the entire tumor cannot be resected, which is often the case.
Gigantism and acromegaly are usually caused by a pituitary adenoma that secretes excessive amounts of growth hormone (GH); rarely, they are caused by non-pituitary tumors that secrete growth hormone–releasing hormone (GHRH).
Gigantism occurs if GH hypersecretion begins in childhood, before closure of the epiphyses.
Acromegaly involves GH hypersecretion beginning in adulthood; a variety of bony and soft tissue abnormalities develop.
Diagnose by measuring insulin-like growth factor 1 and GH levels; do central nervous system imaging to detect a pituitary tumor.
Remove pituitary tumors surgically or using radiation therapy.
If tumors cannot be removed, give octreotide or lanreotide to suppress GH secretion.